A. Mackensen, G. Carcelain, and S. Viel, Direct evidence to support the immunosurveillance concept in a human regressive melanoma., Journal of Clinical Investigation, vol.93, issue.4, pp.1397-1402, 1994.
DOI : 10.1172/JCI117116

URL : http://www.jci.org/articles/view/117116/files/pdf

C. Jandus, D. Speiser, and P. Romero, Recent advances and hurdles in melanoma immunotherapy, Pigment Cell & Melanoma Research, vol.5, issue.Suppl 2, pp.711-723, 2009.
DOI : 10.4049/jimmunol.175.10.7046

URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1755-148X.2009.00634.x/pdf

F. S. Hodi, S. J. O-'day, and D. F. Mcdermott, Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-723, 2010.
DOI : 10.1056/NEJMoa1003466

URL : http://www.nejm.org/doi/pdf/10.1056/NEJMoa1003466

C. Robert, L. Thomas, and I. Bondarenko, Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, New England Journal of Medicine, vol.364, issue.26, pp.2517-2526, 2011.
DOI : 10.1056/NEJMoa1104621

C. Robert, J. Schachter, and G. V. Long, Pembrolizumab versus Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.372, issue.26, pp.2521-2532, 2015.
DOI : 10.1056/NEJMoa1503093

C. Robert, G. V. Long, and B. Brady, Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-330, 2015.
DOI : 10.1056/NEJMoa1412082

URL : https://hal.archives-ouvertes.fr/hal-00699117

L. M. Muul, P. J. Spiess, E. P. Director, and S. A. Rosenberg, Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma, Journal of Immunology, vol.138, pp.989-995, 1987.

S. A. Rosenberg and N. P. Restifo, Adoptive cell transfer as personalized immunotherapy for human cancer, Science, vol.385, issue.224, pp.62-68, 2015.
DOI : 10.1016/S0140-6736(14)61403-3

M. J. Besser, R. Shapira-frommer, and A. J. Treves, Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients, Clinical Cancer Research, vol.16, issue.9, pp.2646-2655, 2010.
DOI : 10.1158/1078-0432.CCR-10-0041

M. E. Dudley, J. R. Wunderlich, and P. F. Robbins, Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes, Science, vol.298, issue.5594, pp.850-854, 2002.
DOI : 10.1126/science.1076514

URL : http://europepmc.org/articles/pmc1764179?pdf=render

M. E. Dudley, C. A. Gross, and R. P. Somerville, -Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma, Journal of Clinical Oncology, vol.31, issue.17, pp.2152-2159, 2013.
DOI : 10.1200/JCO.2012.46.6441

URL : http://europepmc.org/articles/pmc3731980?pdf=render

E. Ellebaek, T. Z. Iversen, and N. Junker, Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients, Journal of Translational Medicine, vol.10, issue.1, p.169, 2012.
DOI : 10.1158/1078-0432.CCR-11-2515

URL : https://translational-medicine.biomedcentral.com/track/pdf/10.1186/1479-5876-10-169?site=translational-medicine.biomedcentral.com

S. Pilon-thomas, L. Kuhn, and S. Ellwanger, Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma, Journal of Immunotherapy, vol.35, issue.8, pp.615-620, 2012.
DOI : 10.1097/CJI.0b013e31826e8f5f

URL : http://europepmc.org/articles/pmc4467830?pdf=render

M. J. Besser, R. Shapira-frommer, and O. Itzhaki, Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies, Clinical Cancer Research, vol.19, issue.17, pp.4792-4800, 2013.
DOI : 10.1158/1078-0432.CCR-13-0380

B. Dréno, J. M. Nguyen, and A. Khammari, Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma, Cancer Immunology, Immunotherapy, vol.51, issue.10, pp.539-546, 2002.
DOI : 10.1007/s00262-002-0315-1

A. Khammari, J. M. Nguyen, and M. C. Pandolfino, Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma, Cancer Immunology, Immunotherapy, vol.12, issue.3, pp.1853-1860, 2007.
DOI : 10.4049/jimmunol.173.12.7125

N. Labarrière, M. C. Pandolfino, and N. Gervois, Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients, Cancer Immunology, Immunotherapy, vol.51, issue.10, pp.532-538, 2002.
DOI : 10.1007/s00262-002-0313-3

A. Khammari, A. C. Knol, and J. M. Nguyen, Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival, Journal of Immunology Research, vol.20, issue.9, 2014.
DOI : 10.1245/s10434-013-2999-1

URL : http://doi.org/10.1155/2014/186212

V. Vignard, B. Lemercier, and A. Lim, Adoptive Transfer of Tumor-Reactive Melan-A-Specific CTL Clones in Melanoma Patients Is Followed by Increased Frequencies of Additional Melan-A-Specific T Cells, The Journal of Immunology, vol.175, issue.7, pp.4797-4805, 2005.
DOI : 10.4049/jimmunol.175.7.4797

E. A. Eisenhauer, P. Therasse, and J. Bogaerts, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-247, 2009.
DOI : 10.1016/j.ejca.2008.10.026

F. Jotereau, M. C. Pandolfino, and D. Boudart, High-Fold Expansion of Human Cytotoxic T-Lymphocytes Specific for Autologous Melanoma Cells for Use in Immunotherapy, Journal of Immunotherapy, vol.10, issue.6, pp.405-411, 1991.
DOI : 10.1097/00002371-199112000-00003

M. C. Pandolfino, N. Labarrière, and M. H. Tessier, High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement, Cancer Immunology, Immunotherapy, vol.50, issue.3, pp.134-140, 2001.
DOI : 10.1007/PL00006683

N. Gervois, F. Heuze, E. Diez, and F. Jotereau, Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: Cytotoxic activity and T cell receptor gene rearrangements, European Journal of Immunology, vol.1, issue.4, pp.825-831, 1990.
DOI : 10.1002/eji.1830200417

M. C. Pandolfino, S. Saiagh, A. C. Knol, and B. Dreno, Comparison of three culture media for the establishment of melanoma cell lines, Cytotechnology, vol.164, issue.5, pp.403-412, 2010.
DOI : 10.4049/jimmunol.164.1.495

M. Vourc-'h-jourdain, C. Volteau, J. M. Nguyen, A. Khammari, and B. Dreno, Melanoma gene expression and clinical course, Archives of Dermatological Research, vol.12, issue.2, pp.673-679, 2009.
DOI : 10.1093/jnci/94.11.805

T. Jung, U. Schauer, C. Heusser, C. Neumann, and C. Rieger, Detection of intracellular cytokines by flow cytometry, Journal of Immunological Methods, vol.159, issue.1-2, pp.197-207, 1993.
DOI : 10.1016/0022-1759(93)90158-4

I. M. Svane and E. M. Verdegaal, Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?, Cancer Immunology, Immunotherapy, vol.14, issue.8, pp.1081-1091, 2014.
DOI : 10.1016/S1470-2045(12)70539-9

A. Khammari, J. M. Nguyen, and M. Saint-jean, Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-??) in metastatic melanoma patients, Cancer Immunology, Immunotherapy, vol.2013, issue.7, pp.805-815, 2015.
DOI : 10.1155/2013/932318

G. J. Ullenhag, A. M. Sadeghi, and B. Carlsson, Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy, Proceedings of the National Academy of Sciences of the United States of America, pp.725-732, 2002.
DOI : 10.1097/CJI.0b013e3181f05b91

A. C. Knol, F. Lemaître, and M. C. Pandolfino, expansion of tumor-infiltrating lymphocytes in melanoma patients, Experimental Dermatology, vol.168, issue.5, pp.436-445, 2008.
DOI : 10.4049/jimmunol.168.10.4864

X. Yao, M. Ahmadzadeh, and Y. C. Lu, Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer, Blood, vol.119, issue.24, pp.5688-5696, 2012.
DOI : 10.1182/blood-2011-10-386482

URL : http://www.bloodjournal.org/content/bloodjournal/119/24/5688.full.pdf